

DIFFERENCES IN BINDING SITE CONFORMATIONS BETWEEN SUBSTRATE-BOUND AND INHIBITOR-BOUND DOPAMINE (DAT), SEROTONIN (SERT) AND NORADRENALIN (NET) TRANSPORTERS

Ravna AW^a, Gabrielsen M^a, Kristiansen K^a, Dahl S^a, Chilmonczyk Z^b, Bojarski AJ^c, Sylte I^a

^aMedical Pharmacology and Toxicology, Department of Medical Biology, Faculty of Health Sciences, University of Tromsø, N-9037 Tromsø, Norway; ^bNational Institute of Medicines, Chelmska 30/34, 00-725 Warsaw, Poland;

^cInstitute of Pharmacology, Polish Academy of Sciences, Smetna 12, 31-343 Kraków, Poland

Introduction

The dopamine (DAT), serotonin (SERT) and noradrenalin (NET) transporters are molecular targets for different classes of psychotropic drugs. Cocaine and the SSRI S-citalopram block neurotransmitter reuptake competitively, but while cocaine is a non-selective reuptake inhibitor, S-citalopram is a selective SERT inhibitor.¹ Site directed mutagenesis studies indicate that cocaine and S-citalopram bind in the same binding site as the substrate.²⁻⁴

Aim

Investigation of

- Differences in binding site conformations of occluded and open-outward neurotransmitter transporter models.
- Putative binding modes of cocaine and S-citalopram in DAT, NET and SERT.

Methods

The crystal structures of *Aquifex aeolicus* LeuT_{Aa} complexed with a substrate (leucine) in an occluded conformation⁵ (PDB id 2a65), and with an inhibitor (tryptophane) in an open-to-out conformation⁶ (PDB id 3f3a), were used as templates for molecular modeling of DAT, SERT and NET using the ICM version 3.6.⁷ ICMPocketFinder was used to investigate differences in binding site size and shape between the occluded conformation and open-to-out conformation. Cocaine and S-citalopram were docked into DAT, SERT, and NET.

Results & Discussion

The occluded and open-outward DAT models, with substrate binding pockets displayed, are shown in Figure 1. Two ligand binding pockets ("S1" (substrate




Figure 1

Backbone Ca-traces of occluded DAT model (A) and Open-to-out DAT model (B) viewed in the membrane plane, cytoplasm downwards. Binding sites as detected by ICMPocketFinder are displayed in yellow (S1) and green (S2) (A); and in yellow (B). Coloring of the C-alpha traces of the model is blue via white to red from N-terminal to C-terminal.




Figure 2

Close-up view of differences in the "Tyrosine-Phenylalanine Gate" between the occluded (green) and open-to-out (purple) DAT (A), NET (B), and SERT (C) models.

binding site) and "S2" (putative extracellular binding site) were detected in the occluded conformation, while in the open-to-out conformation the binding sites were "fused" and overlapping, yielding one large ligand binding pocket. A conserved tyrosine and a conserved phenylalanine formed a gate between the putative binding pockets in the occluded conformation, and the distance between these two amino acids was longer in the open to out conformation (Figure 2).

Figure 3 shows cocaine and S-citalopram docked into the open-to-out conformations of DAT, NET and SERT. The majority of the amino acids in the substrate binding sites of DAT, NET and SERT consist of conserved amino acids. However, there are differences in TMH1 and TMH8 (DAT: Phe75, Ala423, Gly425; NET: Phe72, Ser420, Gly422; SERT: Tyr95, Thr439, Ala441). In the docking studies, the nitril group of S-citalopram interacted with these three amino acids in each of the transporters. In contrast, the cocaine molecule did not reach this area of TMH8 in the binding site.




Figure 3

Cocaine and S-citalopram docked into DAT, NET and SERT models. A. Cocaine docked into DAT; B. Cocaine docked into NET; C. Cocaine docked into SERT; D. S-citalopram docked into DAT; E. S-citalopram docked into NET; F. S-citalopram docked into SERT. Non-conserved amino acids in TMH1 and TMH8, and the conserved aspartate in TMH1 and tyrosine in TMH3, are displayed as sticks. Color coding: C-alpha traces blue via white to red from N-terminal to C-terminal; sticks colored according to atom type (C = white (protein), yellow (ligand); H = grey; O = red; N = blue; F = green).

References

1. Tatsumi M, Groshan K, Blakeley RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. *Eur J Pharmacol* 1997;340(2-3):249-258.

2. Chen JG, Sachpatzidis A, Rudnick G. The third transmembrane domain of the serotonin transporter contains residues associated with substrate and cocaine binding. *J Biol Chem* 1997;272(45):28321-28327.

3. Kitayama S, Shimada S, Xu H, Markham L, Donovan DM, Uhl GR. Dopamine transporter site-directed mutations differentially alter substrate

transport and cocaine binding. *Proc Natl Acad Sci U S A* 1992;89(16):7782-7785.

4. Lee SH, Chang MY, Lee KH, Park BS, Lee YS, Chin HR, Lee YS. Importance of valine at position 152 for the substrate transport and 2beta-carbomethoxy-3beta-(4-fluorophenyl)tropane binding of dopamine transporter. *Mol Pharmacol* 2000;57(5):883-889.

5. Yamashita A, Singh SK, Kawata T, Iin Y, Gouaux E. Crystal structure of a bacterial homologue of Na⁺/Cl⁻-dependent neurotransmitter transporters. *Nature* 2005;437(7056):215-223.

6. Singh SK, Piscitelli CL, Yamashita A, Gouaux E. A competitive inhibitor traps LeuT in an open-to-out conformation. *Science* 2008;322(5908):1655-1661.

7. Abagyan R, Totrov M, Kuznetsov DN. ICM - a new method for protein modeling and design. Applications to docking and structure prediction from the distorted native conformation. *J Comp Chem* 1994;15:488-506.